Inhibition of CNS Remyelination by the Presence of Semaphorin 3A
- Yasir A. Syed1,2,3,
- Elisabeth Hand2,
- Wiebke Möbius2,
- Chao Zhao4,
- Matthias Hofer1,
- Klaus A. Nave2, and
- Mark R. Kotter1,2,3
- 1Anne McLaren Laboratory for Regenerative Medicine, Medical Research Council Centre for Stem Cell Biology and Regenerative Medicine, University of Cambridge, Forvie Site, Cambridge, CB2 0SZ, United Kingdom,
- 2Max Planck Institute for Experimental Medicine, 37075 Goettingen, Germany,
- 3Department of Neurosurgery, Medical University Vienna, 1090 Vienna, Austria, and
- 4Neurosciences, MRC Centre for Stem Cell Biology and Regenerative Medicine, University of Cambridge, Department of Veterinary Medicine, Cambridge CB3 0ES, United Kingdom
Abstract
Failure of oligodendrocyte precursor cell (OPC) differentiation has been recognized as the leading cause for the failure of myelin regeneration in diseases such as multiple sclerosis (MS). One explanation for the failure of OPC differentiation in MS is the presence of inhibitory molecules in demyelinated lesions. So far only a few inhibitory substrates have been identified in MS lesions. Semaphorin 3A (Sema3A), a secreted member of the semaphorin family, can act as repulsive guidance cue for neuronal and glial cells in the CNS. Recent studies suggest that Sema3A is also expressed in active MS lesions. However, the implication of Sema3A expression in MS lesions remains unclear as OPCs are commonly present in chronic demyelinated lesions. In the present study we identify Sema3A as a potent, selective, and reversible inhibitor of OPC differentiation in vitro. Furthermore, we show that administration of Sema3A into demyelinating lesions in the rat CNS results in a failure of remyelination. Our results imply an important role for Sema3A in the differentiation block occurring in MS lesions.
- Copyright © 2011 the authors 0270-6474/11/313719-10$15.00/0





